Fettstoffwechsel: Diagnostik und Therapie

Fettstoffwechselstörungen sind sowohl in der allgemeinen Bevölkerung als auch bei Patienten mit Diabetes mellitus häufig. Ihre Therapie leistet einen wichtigen Beitrag bei der primären und sekundären Prävention kardiovaskulärer Erkrankungen. Dieser Beitrag fasst den aktuellen Stand von pathophysiologischen, diagnostischen und therapeutischen Aspekten von Fettstoffwechselstörungen unter dem Gesichtspunkt der kardiovaskulären Prävention zusammen.

Abstract

Lipid disorders are common both in the general population and in patients with diabetes mellitus. The therapy makes an important contribution to the primary and secondary prevention of cardiovascular disease. In patients without diabetes, the focus is on LDL cholesterol. In patients with diabetes, non-HDL cholesterol and elevated triglycerides deserve special attention. In some cases, extremely high triglycerides can result in acute pancreatitis. This article summarizes the current status of the pathophysiological, diagnostic and therapeutic aspects of lipid disorders from the point of view of cardiovascular prevention.

Kernaussagen

• Die cholesterinsenkende Therapie ist ein wichtiger Baustein der kardiovaskulären Prävention.

• Die lipidologische Prävention erfolgt risikoadaptiert als zielwertgerechte Stufentherapie.

• Neben Lebensstilmaßnahmen ist die Gabe von Statinen die zentrale Maßnahme.

• Weitere Therapeutika sind Ezetimib, Bempedoinsäure und Inhibitoren von PCSK9.

• Ultima Ratio ist die Lipidapherese.

• Derzeit wird ein Großteil der Patienten nicht zielwertgerecht therapiert.

Schlüsselwörter

LDL-Cholesterin - kardiovaskuläres Risiko - Lipidtherapie - Prävention

Keywords

LDL cholesterol - cardiovascular risk - lipid therapy - prevention

Publication History

Article published online:
21 February 2022

• Literatur

• 1 Anitschkow N. Über Veränderungen der Kaninchenaorta bei experimenteller Cholesteatose. Beitr Pathol Anat 1913; 56: 379-404
• 2 Grundy SM, Cleeman JI, Merz CN. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239 DOI: 10.1016/j.jacc.2004.07.001. (PMID: 15358046)
• 3 Ference BA, Majeed F, Penumetcha R. et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2×2 factorial Mendelian randomization study. J Am Coll Cardiol 2015; 65: 1552-1561 DOI: 10.1016/j.jacc.2015.02.020. (PMID: 25770315)
• 4 Timpson NJ, Lawlor DA, Harbord RM. et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005; 366: 1954-1959 DOI: 10.1016/S0140-6736(05)67786-0. (PMID: 16325697)
• 5 Nordestgaard BG, Tybjaerg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol 2011; 22: 113-122 DOI: 10.1097/MOL.0b013e32834477d2. (PMID: 21358543)
• 6 Buchwald H, Varco RL, Matts JP. et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-955 DOI: 10.1056/NEJM199010043231404.
• 7 Merkel M. Diabetische Dyslipidämie. Dtsch Med Wochenschr 2021; 146: 85-91 DOI: 10.1055/a-1202-3165. (PMID: 33465804)
• 8 Boekholdt SM, Arsenault BJ, Mora S. et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302-1309 DOI: 10.1001/jama.2012.366. (PMID: 22453571)
• 9 Framingham Heart Study. 2018 ACSVD 10-year Risk Calculator. 2018 www.framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-10-year-risk/
• 10 Assmann-Stiftung fü, r Prävention. PROCAM-Gesundheitstest. 2018 www.assmann-stiftung.de/procam-tests/
• 11 European Society of Cardiology. SCORE Risk Charts. 2021 http://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-Risk-Charts
• 12 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; 41: 111-188 DOI: 10.1093/eurheartj/ehz455. (PMID: 31504418)
• 13 Estruch R, Ros E, Martinez-Gonzalez MA. Mediterranean diet for primary prevention of cardiovascular disease. N Engl J Med 2013; 369: 676-677 DOI: 10.1056/NEJMc1306659. (PMID: 30281995)
• 14 Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015; 385: 1397-1405 DOI: 10.1016/S0140-6736(14)61368-4.
• 15 Collins R, Reith C, Emberson J. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561 DOI: 10.1016/S0140-6736(16)31357-5. (PMID: 27616593)
• 16 Stroes ES, Thompson PD, Corsini A. et al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-1022 DOI: 10.1093/eurheartj/ehv043. (PMID: 25694464)
• 17 Sattar N, Preiss D, Murray HM. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742 DOI: 10.1016/S0140-6736(09)61965-6. (PMID: 20167359)
• 18 Cannon CP, Blazing MA, Giugliano RP. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-2397 DOI: 10.1056/NEJMc1509363. (PMID: 26039521)
• 19 Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc Drugs Ther 2021; DOI: 10.1007/s10557-020-07139-x..
• 20 Sabatine MS, Giugliano RP, Keech AC. et al. Evolocumab and Clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 377: 787-788 DOI: 10.1056/NEJMoa1615664. (PMID: 28304224)
• 21 McCullough PA, Ballantyne CM, Sanganalmath SK. et al. Efficacy and Safety of alirocumab in high-risk patients with clinical atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia (from 5 placebo-controlled ODYSSEY Trials). Am J Cardiol 2018; 121: 940-948 DOI: 10.1016/j.amjcard.2017.12.040. (PMID: 29472008)
• 22 Chandra Ghosh G, Bandyopadhyay D, Ghosh RK. et al. Effectiveness and Safety of inclisiran, a novel long-acting RNA therapeutic inhibitor of proprotein convertase subtilisin/kexin 9. Am J Cardiol 2018; 122: 1272-1277 DOI: 10.1016/j.amjcard.2018.06.023. (PMID: 30075894)
• 23 Kommission Therapeutische Apherese der Deutschen Gesellschaft für Nephrologie. Apherese-Standard. 2019 http://www.dgfn.eu/apherese-standard.html
• 24 Kotseva K, De Backer G, De Bacquer D. et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 2019; 26: 824-835 DOI: 10.1177/2047487318825350. (PMID: 30739508)